Drug Profile
Research programme: antibody and protein-based therapeutics - Vitesse Biologics
Latest Information Update: 28 Jul 2019
Price :
$50
*
At a glance
- Originator Vitesse Biologics
- Class Antibodies; Proteins
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Haematological disorders; Immunological disorders
Most Recent Events
- 28 Jul 2019 No recent reports of development identified for research development in Cancer in USA
- 28 Jul 2019 No recent reports of development identified for research development in Haematological-disorders in USA
- 28 Jul 2019 No recent reports of development identified for research development in Immunological-disorders in USA